Company news

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news

Aclaris Therapeutics, Inc. news releases on 6ix. Latest, Sep 3, 2026: Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news

Press releases & updates

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indicati...

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Aclaris Therapeutics to Participate in Two February Healthcare Conferences

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Aclaris Therapeutics Announces Leadership Transition

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million